Brief: Antengene Corp Announces Approval Of Phase I/II Study Of Selinexor (ATG-010) In China
19/11/2021 01:05
Nov 19 (Reuters) - Antengene Corporation Ltd 6996.HK :
* ANNOUNCES APPROVAL OF PHASE I/II STUDY OF SELINEXOR
(ATG-010) IN
PATIENTS WITH NON-HODGKIN LYMPHOMA IN CHINA
Further company coverage: 6996.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Antengene
See all newsBiotech firm Antengene's H1 revenue jumps on licensing deals
Brief: Antengene Corp Expects HY Profit Of RMB195 MLN-RMB238 MLN
Brief: Antengene Corp Receives Initial $60 Million Upfront Payment From UCB
Brief: Antengene Corp Intends To Repurchase Up To 67.92 Million Shares
Brief: Antengene Corp Enters Exclusive License Agreement With K2 Therapeutics For Atg-106